Infections in Patients with Autoimmune Diseases

  • Neil U. Parikh
  • Mark F. Sands
  • Stanley A. SchwartzEmail author


The relationship between autoimmunity and infections is complex and bi-directional. Infections have been associated with the induction of autoimmunity as well as protection from autoimmune diseases. Infectious agents may play both a causative and protective role in the pathogenesis of some autoimmune disorders like Sjogren’s syndrome. Infections are a common cause of morbidity and mortality in patients with systemic autoimmune diseases. Considerable evidence has emerged regarding the greater susceptibility of patients with autoimmune disorders to infections due to predisposition from autoimmunity itself as well as the use of immunosuppressive therapy.


  1. 1.
    Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev. 2008;8(1):24–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Kallenberg CG, Tadema H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to “autoimmunity and infection”. Autoimmun Rev. 2008;8(1):29–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infections. Autoimmun Rev. 2008;8(1):36–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Sotgiu S, Angius A, Embry A, Rosati G, Musumeci S. Hygiene hypothesis: innate immunity, malaria and multiple sclerosis. Med Hypotheses. 2008;70(4):819–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Zandman-Goddard G, Shoenfeld Y. Parasitic infection and autoimmunity. Lupus. 2009;18(13):1144–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Sheikh KA, Nachamkin I, Ho TW, Willison HJ, Veitch J, Ung H, et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. Neurology. 1998;51(2):371–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Kivity S, Arango MT, Ehrenfeld M, Tehori O, Shoenfeld Y, Anaya JM, et al. Infection and autoimmunity in Sjogren’s syndrome: a clinical study and comprehensive review. J Autoimmun. 2014;51:17–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8(2):153–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri S, Bayry J. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 2010;6(11):e1001077.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cunningham MW. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol. 2014;33(4):314–29.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Root-Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep. 2014;14(1):407.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80–94.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol. 1996;8(6):831–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today. 1993;14(5):203–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Root-Bernstein R. Antigenic complementarity in the induction of autoimmunity: a general theory and review. Autoimmun Rev. 2007;6(5):272–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Doria A, Zampieri S, Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev. 2008;8(2):89–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev. 2008;8(2):116–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Ryan KR, Patel SD, Stephens LA, Anderton SM. Death, adaptation and regulation: the three pillars of immune tolerance restrict the risk of autoimmune disease caused by molecular mimicry. J Autoimmun. 2007;29(4):262–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Zignego AL, Piluso A, Giannini C. HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation. Autoimmun Rev. 2008;8(2):107–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol. 2010;45(3):266–76.CrossRefPubMedGoogle Scholar
  21. 21.
    Packey CD, Sartor RB. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med. 2008;263(6):597–606.CrossRefPubMedGoogle Scholar
  22. 22.
    Teng F, Klinger CN, Felix KM, Bradley CP, Wu E, Tran NL, et al. Gut microbiota drive autoimmune arthritis by promoting differentiation and migration of Peyer’s patch T follicular helper cells. Immunity. 2016;44(4):875–88.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Caza T, Oaks Z, Perl A. Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol. 2014;33(4):330–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Jonsson G, Truedsson L, Sturfelt G, Oxelius VA, Braconier JH, Sjoholm AG. Hereditary C2 deficiency in Sweden. Medicine (Baltimore). 2005;84(1):23–34.CrossRefGoogle Scholar
  25. 25.
    Iguchi-Hashimoto M, Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ishikawa M, et al. The association between serious infection and disease outcome in patients with rheumatoid arthritis. Clin Rheumatol. 2016;35(1):213–8.CrossRefPubMedGoogle Scholar
  26. 26.
    al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 1993;13(1):58–67.CrossRefPubMedGoogle Scholar
  27. 27.
    Fox RI. Sjogren’s syndrome. Lancet. 2005;366(9482):321–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Mandl T, Bredberg A, Jacobsson LT, Manthorpe R, Henriksson G. CD4+ T-lymphocytopenia – a frequent finding in anti-SSA antibody seropositive patients with primary Sjogren’s syndrome. J Rheumatol. 2004;31(4):726–8.PubMedGoogle Scholar
  29. 29.
    Hersey P, Lawrence S, Prendergast D, Bindon C, Benson W, Valk P. Association of Sjögren’s syndrome with C4 deficiency, defective reticuloendothelial function and circulating immune complexes. Clin Exp Immunol. 1983;52(3):551–60.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Hammarström L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol. 2000;120(2):225–31.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bloom KA, Chung D, Cunningham-Rundles C. Osteoarticular infectious complications in patients with primary immunodeficiencies. Curr Opin Rheumatol. 2008;20(4):480–5.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol (Orlando, Fla). 1999;92(1):34–48.CrossRefGoogle Scholar
  33. 33.
    Cunningham-Rundles C. Physiology of IgA and IgA deficiency. J Clin Immunol. 2001;21(5):303–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Yel L. Selective IgA deficiency. J Clin Immunol. 2010;30(1):10–6.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jorgensen GH, Gardulf A, Sigurdsson MI, Sigurdardottir ST, Thorsteinsdottir I, Gudmundsson S, et al. Clinical symptoms in adults with selective IgA deficiency: a case-control study. J Clin Immunol. 2013;33(4):742–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Wang N, Shen N, Vyse TJ, Anand V, Gunnarson I, Sturfelt G, et al. Selective IgA deficiency in autoimmune diseases. Mol Med. 2011;17(11–12):1383–96.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Matsumoto R, Nakamizo S, Tanioka M, Miyachi Y, Kabashima K. Leukocytoclastic vasculitis with eosinophilic infiltration in an HIV-positive patient. Eur J Dermatol: EJD. 2011;21(1):103–4.PubMedGoogle Scholar
  38. 38.
    Iordache L, Launay O, Bouchaud O, Jeantils V, Goujard C, Boue F, et al. Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmun Rev. 2014;13(8):850–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002;1(6):329–37.CrossRefPubMedGoogle Scholar
  40. 40.
    Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, et al. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2009;48(1):123–32.CrossRefGoogle Scholar
  41. 41.
    Savige JA, Chang L, Horn S, Crowe SM. Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity. 1994;18(3):205–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Ahmad DS, Esmadi M, Steinmann WC. Idiopathic CD4 Lymphocytopenia: spectrum of opportunistic infections, malignancies, and autoimmune diseases. Avicenna J Med. 2013;3(2):37–47.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Regent A, Autran B, Carcelain G, Cheynier R, Terrier B, Charmeteau-De Muylder B, et al. Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients. Medicine (Baltimore). 2014;93(2):61–72.CrossRefGoogle Scholar
  44. 44.
    Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–23.CrossRefPubMedGoogle Scholar
  45. 45.
    Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94(6):557–72.CrossRefGoogle Scholar
  46. 46.
    Migita K, Arai T, Ishizuka N, Jiuchi Y, Sasaki Y, Izumi Y, et al. Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy. PLoS One. 2013;8(11):e78699.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Cutolo M, Otsa K, Aakre O, Sulli A. Nocturnal hormones and clinical rhythms in rheumatoid arthritis. Ann N Y Acad Sci. 2005;1051:372–81.CrossRefPubMedGoogle Scholar
  48. 48.
    Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, et al. Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol. 2008;26(1 Suppl 48):S67–73.PubMedGoogle Scholar
  49. 49.
    Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168–73.PubMedGoogle Scholar
  50. 50.
    Caporali R, Caprioli M, Bobbio-Pallavicini F, Montecucco C. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139–43.CrossRefPubMedGoogle Scholar
  51. 51.
    Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy. 2002;22(9):1157–62.CrossRefPubMedGoogle Scholar
  52. 52.
    Albrecht K, Muller-Ladner U. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S95–101.PubMedGoogle Scholar
  53. 53.
    McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford). 2009;48(8):867–71.CrossRefGoogle Scholar
  54. 54.
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98.CrossRefPubMedGoogle Scholar
  55. 55.
    Cavallasca JA, Costa CA, Maliandi MDR, Contini LE, Fernandez de Carrera E, Musuruana JL. Severe infections in patients with autoimmune diseases treated with cyclophosphamide. Reumatol Clín (Engl Ed). 2015;11(4):221–3.CrossRefGoogle Scholar
  56. 56.
    Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–65.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.Google Scholar
  58. 58.
    de Assis MR, Heymann RE. Care against infections in rheumatic autoimmune diseases. Rev Bras Reumatol. 2015;55(4):317.CrossRefPubMedGoogle Scholar
  59. 59.
    Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev. 2008;8(2):147–52.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev. 2008;8(2):100–3.CrossRefPubMedGoogle Scholar
  61. 61.
    Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev. 2008;8(2):104–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester G-R, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48(4):927–34.CrossRefPubMedGoogle Scholar
  63. 63.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806.CrossRefPubMedGoogle Scholar
  64. 64.
    Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625–32.CrossRefPubMedGoogle Scholar
  65. 65.
    Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab – for how long? J Allergy Clin Immunol. 2015;136(5):1407–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2(5):594–600.CrossRefPubMedGoogle Scholar
  67. 67.
    Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353(11):1114–23.CrossRefPubMedGoogle Scholar
  68. 68.
    Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2016;75:1108–13.CrossRefPubMedGoogle Scholar
  69. 69.
    Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30(1–2):90–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Lee IH, Kang GW, Kim KC. Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis. Rheumatol Int. 2016 Jul;36(7):1027–32.CrossRefPubMedGoogle Scholar
  71. 71.
    Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA. International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001 Apr;44(4):912–20.CrossRefPubMedGoogle Scholar
  72. 72.
    Schwartz SA. Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol. 1990;10(2):81–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5(8):433–41.CrossRefPubMedGoogle Scholar
  75. 75.
    Elluru SR, Vani J, Delignat S, Bloch MF, Lacroix-Desmazes S, Kazatchkine MD, et al. Modulation of human dendritic cell maturation and function by natural IgG antibodies. Autoimmun Rev. 2008;7(6):487–90.CrossRefPubMedGoogle Scholar
  76. 76.
    Meyer-Olson D, Witte T. Immunology: prevention of infections in patients with autoimmune diseases. Nat Rev Rheumatol. 2011;7(4):198–200.CrossRefPubMedGoogle Scholar
  77. 77.
    Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev. 2008;8(2):124–8.CrossRefPubMedGoogle Scholar
  78. 78.
    Murdaca G, Orsi A, Spano F, Puppo F, Durando P, Icardi G, et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev. 2014;13(2):75–84.CrossRefPubMedGoogle Scholar
  79. 79.
    Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135–45.CrossRefPubMedGoogle Scholar
  80. 80.
    Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–804.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Neil U. Parikh
    • 1
  • Mark F. Sands
    • 2
  • Stanley A. Schwartz
    • 2
    Email author
  1. 1.University of Central FloridaOrlandoUSA
  2. 2.Division of Allergy, Immunology & Rheumatology, Department of MedicineUniversity at Buffalo, Buffalo General Medical CenterBuffaloUSA

Personalised recommendations